HIMS Stock Gains As FDA Reportedly Moves Toward Lifting Restrictions On Peptides

Hims & Hers Health Inc. (HIMS) shares surged on Tuesday morning amid a report stating that the U.S. Food and Drug Administration is moving to lift restrictions on peptides.

According to a report by The New York Times, the FDA is moving to allow compounding pharmacies to manufacture over a dozen injectable peptides that were previously banned due to potential safety risks.

This decision would reverse a 2023 ban that resulted in the removal of 14 peptides from a list of products that the FDA allowed compounding pharmacies to produce.

Shares of Hims & Hers, which provides compounded medications, surged nearly 6% in Tuesday morning’s trade.

Get updates to this developing story directly on Stocktwits.

Also See: Buffett Says He Sold Apple Shares Too Soon, But Does Not Regret It: Report

For updates and corrections, email newsroom[at]stocktwits[dot]com.